Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose... by Alistar, Angela, Dr, Morris, Bonny B, MSPH, Desnoyer, Rodwige, MD, Klepin, Heidi D, MD, Hosseinzadeh, Keyanoosh, MD, Clark, Clancy, MD, Cameron, Amy, PA, Leyendecker, John, Prof, D'Agostino, Ralph, Prof, Topaloglu, Umit, PhD, Boteju, Lakmal W, PhD, Boteju, Asela R, ASc, Shorr, Rob, PhD, Zachar, Zuzana, PhD, Bingham, Paul M, PhD, Ahmed, Tamjeed, MD, Crane, Sandrine, MD, Shah, Riddhishkumar, MD, Migliano, John J, MD, Pardee, Timothy S, MD, Miller, Lance, PhD, Hawkins, Gregory, PhD, Jin, Guangxu, PhD, Zhang, Wei, Prof, Pasche, Boris, Prof

Get full text